LAVAL, QC, April 27 /PRNewswire-FirstCall/ - Labopharm Inc. today announced that its 2007 Annual Meeting of Shareholders will be held on Wednesday, May 9, 2007 at 11:00 a.m. ET at The Montreal Museum of Fine Arts, Maxwell Cummings Auditorium, 1379 Sherbrooke Street West Montreal, Quebec.
A live webcast of the meeting will be available at www.labopharm.com. Please connect at least 15 minutes prior to the meeting to ensure adequate time for any software download that may be required to join the webcast. The webcast will be archived at the above website for 30 days.
About Labopharm Inc.
Labopharm Inc. is an international specialty pharmaceutical company focused on the development of drugs incorporating the Company’s proprietary advanced controlled-release technologies. The Company’s lead product, a once-daily formulation of the analgesic tramadol, has been approved and launched in Europe and is currently under review for approval by the U.S. Food and Drug Administration. For more information, please visit www.labopharm.com.
This press release contains forward-looking statements, which reflect the Corporation’s current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors, including the uncertainties related to the regulatory process and the commercialization of the Corporation’s products thereafter, if they are approved. Investors should consult the Corporation’s ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Corporation disclaims any obligation to update these forward-looking statements.
Labopharm Inc.
CONTACT: At Labopharm: Mark D’Souza, Chief Financial Officer, Tel: (450)686-0207; Sophie Coulombe, Manager, Legal, Corporate Affairs andCommunications, Tel: (450) 680-3221; At The Equicom Group: Jason Hogan,Media and Investor Relations, Tel: (416) 815-0700, jhogan@equicomgroup.com;French: Eric Bouchard, Tel: (514) 844-7997, ebouchard@equicomgroup.com
